Galectin-3 Blockade in Patients With High Blood Pressure
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Modified Citrus Pectin (MCP) vs placebo
Sponsored by

About this trial
This is an interventional prevention trial for Hypertension focused on measuring Hypertension, Galectin 3, Fibrosis, Vascular Stiffness, Echocardiography
Eligibility Criteria
Inclusion Criteria:
- Age 21-70 years
- Physician diagnosed hypertension on stable therapy for 3 months
- Elevated galectin-3 level (above sex-specific median based on Framingham Heart Study measures)
- Able to understand the protocol and provide informed consent in English
Exclusion Criteria:
- Uncontrolled hypertension, defined as systolic blood pressure > 170mmHg, diastolic blood pressure > 100mmHg
- Evidence of secondary hypertension
- History of heart failure, coronary artery disease, stroke, atrial fibrillation
- Left ventricular ejection fraction < 45% on echocardiography
- Use of aldosterone antagonists
- History of liver cirrhosis
- History of pulmonary fibrosis
- Kidney dysfunction, defined as estimated glomerular filtration rate < 45 ml/min/1.73m2
- Anemia, defined as hematocrit < 37% in men and < 34% in women
- Use of chelating agents
- History of Active cancer or malignancy
- Known pregnancy, those unwilling to avoid pregnancy during the course of the study, or women currently breastfeeding
- Hyperkalemia on screening labs, defined as potassium >5.2
- Anticipated inability to complete or comply with study protocol
- History of angioedema
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Modified Citrus Pectin (MCP)
Placebo
Arm Description
Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day
Matched placebo 5 grams by mouth three times a day
Outcomes
Primary Outcome Measures
Change in markers of collagen metabolism
Primary aim will be change in markers of collagen metabolism (PICP, PIIICP, ICTP, TIMP-1) in MCP versus placebo groups over 6 months of treatment.
Secondary Outcome Measures
Change in galectin-3 level
Changes in galectin-3 level from baseline until 6 months will be compared between MCP and placebo groups
Changes in cardiac structure and function
Changes in cardiac structure and function will be examined using 2-D echocardiography and tissue Doppler imaging. This will include changes in left ventricular mass, dimensions, left atrial size, and left ventricular diastolic function.
Changes in arterial stiffness
We will examine changes in arterial stiffness (including augmentation index, carotid-femoral pulse-wave velocity) from baseline to 6 months in the MCP and placebo groups
Full Information
NCT ID
NCT01960946
First Posted
October 9, 2013
Last Updated
February 17, 2021
Sponsor
Massachusetts General Hospital
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT01960946
Brief Title
Galectin-3 Blockade in Patients With High Blood Pressure
Official Title
Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
October 2013 (undefined)
Primary Completion Date
August 30, 2018 (Actual)
Study Completion Date
August 30, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will investigate if Modified Citrus Pectin (MCP) can help people with high blood pressure. MCP is a dietary supplement that is derived from plants, and therefore is not subject to approval by the U.S. Food and Drug Administration (FDA). However, MCP has been deemed as 'generally regarded as safe' by the FDA.
This study will examine whether Modified Citrus Pectin (MCP) can help people with high blood pressure. The study will help understand how MCP may affect the risk for heart disease in patients with high blood pressure.
Detailed Description
Gal-3 appears to be a potential mediator of cardiac fibrosis, preceding the development of clinical heart failure. In this study, we seek to identify individuals at risk for the development of heart failure based on clinical hypertension and elevated Gal-3 concentrations. Participants will be randomized to receive a Gal-3 inhibitor (MCP) or placebo. The primary outcome will be the effect on collagen metabolism, and secondary outcomes include echocardiographic measures of cardiac structure and function, and non-invasive measures of vascular function.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Galectin 3, Fibrosis, Vascular Stiffness, Echocardiography
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
59 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Modified Citrus Pectin (MCP)
Arm Type
Active Comparator
Arm Description
Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matched placebo 5 grams by mouth three times a day
Intervention Type
Dietary Supplement
Intervention Name(s)
Modified Citrus Pectin (MCP) vs placebo
Other Intervention Name(s)
MCP, PectaSol-C
Intervention Description
5 grams by mouth three times a day
Primary Outcome Measure Information:
Title
Change in markers of collagen metabolism
Description
Primary aim will be change in markers of collagen metabolism (PICP, PIIICP, ICTP, TIMP-1) in MCP versus placebo groups over 6 months of treatment.
Time Frame
Baseline and 6 months
Secondary Outcome Measure Information:
Title
Change in galectin-3 level
Description
Changes in galectin-3 level from baseline until 6 months will be compared between MCP and placebo groups
Time Frame
Baseline and 6 months
Title
Changes in cardiac structure and function
Description
Changes in cardiac structure and function will be examined using 2-D echocardiography and tissue Doppler imaging. This will include changes in left ventricular mass, dimensions, left atrial size, and left ventricular diastolic function.
Time Frame
Baseline and 6 months
Title
Changes in arterial stiffness
Description
We will examine changes in arterial stiffness (including augmentation index, carotid-femoral pulse-wave velocity) from baseline to 6 months in the MCP and placebo groups
Time Frame
Baseline and 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age 21-70 years
Physician diagnosed hypertension on stable therapy for 3 months
Elevated galectin-3 level (above sex-specific median based on Framingham Heart Study measures)
Able to understand the protocol and provide informed consent in English
Exclusion Criteria:
Uncontrolled hypertension, defined as systolic blood pressure > 170mmHg, diastolic blood pressure > 100mmHg
Evidence of secondary hypertension
History of heart failure, coronary artery disease, stroke, atrial fibrillation
Left ventricular ejection fraction < 45% on echocardiography
Use of aldosterone antagonists
History of liver cirrhosis
History of pulmonary fibrosis
Kidney dysfunction, defined as estimated glomerular filtration rate < 45 ml/min/1.73m2
Anemia, defined as hematocrit < 37% in men and < 34% in women
Use of chelating agents
History of Active cancer or malignancy
Known pregnancy, those unwilling to avoid pregnancy during the course of the study, or women currently breastfeeding
Hyperkalemia on screening labs, defined as potassium >5.2
Anticipated inability to complete or comply with study protocol
History of angioedema
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer E Ho, MD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33532663
Citation
Lau ES, Liu E, Paniagua SM, Sarma AA, Zampierollo G, Lopez B, Diez J, Wang TJ, Ho JE. Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension. JACC Basic Transl Sci. 2021 Jan 6;6(1):12-21. doi: 10.1016/j.jacbts.2020.10.006. eCollection 2021 Jan.
Results Reference
result
Learn more about this trial
Galectin-3 Blockade in Patients With High Blood Pressure
We'll reach out to this number within 24 hrs